Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    30-October-2000      
Issue 200 Next Update - 14:00 UTC 08:00 EST    31-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Enbrel® (Etanercept) Long-Term Clinical Trial Data


Presented At The American College of Rheumatology Annual Meeting

Patients with moderately to severely active rheumatoid arthritis experienced sustained reduction of joint pain and swelling for as long as four years of treatment with Enbrel(R) (etanercept), according to results from a long-term open-label study. Interim results of this on going study are being presented at the 64th Annual Scientific Meeting of the American College of Rheumatology by Dr. Larry Moreland of the University of Alabama at Birmingham. These data have not been submitted to the U.S. Food and Drug Administration.

In the study, Enbrel continues to be generally well tolerated in patients who have received it for as long as four years. No significant differences in the rate or type of adverse events were seen in these patients treated with Enbrel over time. Infections resulting in hospitalization and/or treatment with IV antibiotics observed in this study have occurred at rates similar to those seen in controlled trials. In those controlled trials, the rates of infection in patients receiving Enbrel and placebo were comparable. No opportunistic infections were reported in the long-term study. There were nine malignancies reported, of various types, similar to the number (12.7) expected in the general population (calculated from the NCI SEER database).

Additional highlights from this long-term study of Enbrel include:

  • -- At 30 months of treatment (n=300), 24 percent of patients experienced no tender joints and 21 percent had no swollen joints.

  • -- Joint improvement was rapid and sustained.

  • -- Steroid use decreased in 59 percent of 337 patients. 29 percent of patients were able to discontinue corticosteroids use, while five percent increased steroid use.

  • -- 479 patients on Enbrel have been followed for more than one year. 420 patients on Enbrel were followed for two years and 164 have been followed for three years. Twelve patients on Enbrel were followed for over four years. All patients in this trial had moderately to severely active rheumatoid arthritis and had failed treatment with one or more disease modifying anti-rheumatic drugs prior to starting Enbrel.

Over two million Americans suffer from the crippling effects of rheumatoid arthritis, a chronic disorder that causes the body's immune system to attack the lining of the joints, resulting in pain, swelling, fatigue and disability. The exact cause of the disease is unknown although biotechnology research has advanced understanding of the role of genes and factors causing inflammation.

ABOUT Enbrel

The U.S. Food and Drug Administration (FDA) has approved Enbrel as a first-line treatment of moderately to severely active rheumatoid arthritis. Enbrel is indicated for reducing signs and symptoms and delaying structural damage in patients with moderately to severely active rheumatoid arthritis.

In postmarketing use, serious infections and sepsis, including fatalities, have been reported. Many of these events occurred in patients predisposed to infections, such as those with advanced or poorly controlled diabetes. Discontinue enbrel in patients with serious infections or sepsis. Do not start enbrel in the presence of sepsis, infection (including chronic or localized), or allergy to enbrel or its components. Use caution in patients predisposed to infection.

Rare cases of central nervous system (CNS) demyelinating disorders have been reported, although the causal relationship to Enbrel remains unclear. Exercise caution when considering Enbrel for patients with these disorders. Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported in RA patients. Exercise caution in patients who have a previous history of significant hematologic abnormalities. Although the causal relationship to Enbrel remains unclear, advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. If significant hematologic abnormalities are confirmed, consider discontinuing Enbrel.

The most frequent adverse events in placebo-controlled clinical trials (n=349) with Enbrel were injection site reactions (ISR) (37%), infections (35%), and headache (17%). Only the rate of ISR was higher than that of placebo. The most frequent adverse events in the methotrexate-controlled trial (n=415) were infections (64%), ISR (34%), and headache (24%). Only the rate of ISR was higher than that of MTX. In all RA patients treated in clinical trials (n=1,197), malignancies were rare (1%).

Enbrel acts by binding tumor necrosis factor (TNF). TNF is one of the dominant cytokines or proteins that play an important role in normal immune function and the cascade of reactions that cause the inflammatory process of RA. Enbrel competitively inhibits the binding of TNF molecules to the TNF receptor (TNFR) sites. The binding of Enbrel to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.